Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment
International Journal of Molecular Sciences · 31.05.2024 · 25 (11) · 6065
DOI: 10.3390/ijms25116065 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.05.2024. Verfasst von Annita-Ioanna Gkioka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens' Medical Scho…. Hauptthemen laut MEDLINE: Multiple Myeloma, MicroRNAs, Lenalidomide, Thalidomide. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IKY Scholarship Programme for PhD candidates in the Greek Universities., Greek Universities.
Abstract (Originalsprache)
MicroRNAs (miRNAs), particularly miR-16 and miR-21, play a crucial role in multiple myeloma (MM) pathogenesis by regulating gene expression. This study evaluated the prognostic significance of circulating miR-16 and miR-21 expression levels in 48 patients with MM at diagnosis treated with lenalidomide–dexamethasone (LD) compared with 15 healthy individuals (HI). All patients were treated with LD, 13 at first line and 35 at relapse, of whom 21 were tested twice at diagnosis and before LD initiation. The results revealed significantly lower levels of miR-16 and miR-21 in patients than in HIs, both at diagnosis and relapse, with decreased miR-16 levels at diagnosis, indicating improved overall survival (OS) (p value 0.024). Furthermore, miR-16 and miR-21 levels were associated with disease markers, while both correlated with the depth of response and mir-16 with sustained response to LD treatment. Ratios of both miR-16 and miR-21 expression levels (prior to LD treatment/diagnosis) below two predicted a shorter time to response (p = 0.027) and a longer time to next treatment (p = 0.042), respectively. These findings suggested a prognostic value for serum miR-16 and miR-21 levels in MM, as their expression levels correlated with disease variables and treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens' Medical School, 11527 Athens, Greece.
- Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 17676 Athens, Greece.
ORCID-Profile: Annita-Ioanna Gkioka, Maria Tsota, Aspasia Koudouna, George V Dedoussis
Förderung
- IKY Scholarship Programme for PhD candidates in the Greek Universities.
- Greek Universities
Zitieren
APA
Gkioka, A. I., Tsota, M., Koudouna, A., Gkiokas, A., Mitropoulou, C. A., Palaiokrassa, A., Alexandropoulos, A., Papadatou-Gigante, M., Bartzi, V., Tryfou, T. M., Sfikakis, P. P., Dedoussis, G. V., & Kyrtsonis, M. C. (2024). Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment. International Journal of Molecular Sciences, 25(11), 6065. https://doi.org/10.3390/ijms25116065
Vancouver
Gkioka AI, Tsota M, Koudouna A, Gkiokas A, Mitropoulou CA, Palaiokrassa A, et al. Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment. International Journal of Molecular Sciences. 2024;25(11):6065. doi:10.3390/ijms25116065
BibTeX
@article{Gkioka2024,
author = {Gkioka, Annita-Ioanna and Tsota, Maria and Koudouna, Aspasia and Gkiokas, Alexandros and Mitropoulou, Christina-Aggeliki and Palaiokrassa, Aikaterini and Alexandropoulos, Alexandros and Papadatou-Gigante, Mavra and Bartzi, Vasiliki and Tryfou, Thomais-Marina and Sfikakis, Petros P and Dedoussis, George V and Kyrtsonis, Marie-Christine},
title = {Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {11},
pages = {6065},
doi = {10.3390/ijms25116065}
}
EUVIMED